Blood Purification

Critical Care Nephrology – Case Report

Treatment of Pyonephritis Complicated by Septic Shock Using Extracorporeal Device Polymyxin B-Hemoperfusion

Amoruso G.a · Di Venosa N.b · Rizzi L.b · Lupo G.b · Gisotti A.b · Vitobello G.b · Mastrandrea P.b · Petta R.b · Cinnella G.a

Author affiliations

aDepartment of Anesthesia and Intensive Care, OORR Riuniti Hospital, University of Foggia, Foggia, Italy
bDepartment of Anesthesia and Intensive Care, Ospedale “L.Bonomo,”, Andria, Italy

Keywords: Polymyxin B-immobilized fiberSepsisSeptic shockBlood purification

Related Articles for ""
Blood Purif 2020;49:627–630
https://doi.org/10.1159/000505611

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Critical Care Nephrology – Case Report

Received: July 12, 2019
Accepted: December 27, 2019
Published online: August 26, 2020
Issue release date: September 2020

Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 1

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Direct hemoperfusion using polymyxin B-immobilized fiber (PMX-DHP) is an established treatment method for septic shock caused by Gram-negative infections. We report one instance in which PMX-DHP therapy has been used successfully in a 33-year-old woman with septic shock from urosepsis. Although there is lack of recommendations in latest Surviving Sepsis Campaign Guidelines, evidence of PMX-DHP efficacy in this subset of patients is growing.

© 2020 S. Karger AG, Basel



Related Articles:

References

  1. Shigemura K, Tanaka K, Adachi M, Yamashita M, Arakawa S, Fujisawa M, et al. Chronological change of antibiotic use and antibiotic resistance in Escherichia coli causing urinary tract infections. J Infect Chemother. 2011 Jan 1;17(5):646–51.
    External Resources
  2. Jiang Y, Li J, Zhang Y, Hu X, Zhang X, Shang X, et al. Clinical situations of bacteriology and prognosis in patients with urosepsis. Biomed Res Int. 2019;2019:1–9.
    External Resources
  3. Suzuki Y, Kojika M, Sato H, Inoue Y, Endo S. Clinical effects of polymyxin B hemoperfusion in patients with septic shock caused by urinary tract infection. Ther Apher Dial. 2019;23(1):80–5.
    External Resources
  4. Weis S, Dickmann P, Pletz MW, Coldewey SM, Gerlach H, Bauer M. The third international consensus definitions for sepsis and septic shock (sepsis-3). Dtsch Arztebl Int. 2017;114(29–30):801–10.
  5. Shimizu T, Miyake T, Tani M. History and current status of polymyxin B-immobilized fiber column for treatment of severe sepsis and septic shock. Ann Gastroenterol Surg. 2017;1(2):105–13.
    External Resources
  6. Zhou F, Peng Z, Murugan R, Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med. 2013;41(9):2209–20.
    External Resources
  7. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445–52.
    External Resources
  8. Esteban E, Ferrer R, Alsina L, Artigas A. Immunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridge. Mediat Inflamm. 2013;2013:1–12.
    External Resources
  9. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S. Suppression of high-mobility group box-1 and receptor for advanced glycation end-product axis by polymyxin B-immobilized fiber hemoperfusion in septic shock patients. J Crit Care. 2011;26(6):546–9.
    External Resources
  10. Takahashi G, Hoshikawa K, Matsumoto N, Shozushima T, Onodera C, Kan S, et al. Changes in serum S100A12 and sRAGE associated with improvement of the PaO2/FiO2 ratio following PMX-DHP therapy for postoperative septic shock. Eur Surg Res. 2011;47(3):135–40.
    External Resources
  11. Srisawat N, Tungsanga S, Lumlertgul N, Komaenthammasophon C, Peerapornratana S, Thamrongsat N, et al. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Crit Care. 2018;22(1):279.
    External Resources
  12. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–77.
    External Resources
  13. Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44(12):2205–12.
    External Resources
  14. Andreis DT, Singer M. Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med. 2016;42(9):1387–97.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Critical Care Nephrology – Case Report

Received: July 12, 2019
Accepted: December 27, 2019
Published online: August 26, 2020
Issue release date: September 2020

Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 1

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2020, Vol.49, No. 5

September 2020

Article

Recommend This
TOP